National Phd in Systems Medicine
Doctoral programme (PhD)
A.Y. 2025/2026
Study area
Medicine and Healthcare
PhD Coordinator
The national doctoral program in Systems Medicine involves the participation of seven universities (UNIMI as the administrative site, Humanitas University, UNIBA, UNICatt, UNINA, UNITN, UNITO) and eight research centers. It is based on three main characteristics: competitive selection, intensive tutoring, and advanced training. The organizational model includes the effective sharing of educational and research activities among the different institutions involved, as well as exchange and mobility of professors and doctoral students, and forms of co-supervision.
Advances in genetics and genomic sciences have triggered a revolution, transforming classical Medicine into what is now known as Precision Medicine. This new approach is based on the acquisition and integration of vast amounts of quantitative molecular data and their use for a personalized definition of disease and targeted therapy. The transition to Precision Medicine requires professionals with new skills and multidisciplinary training.
The national doctoral program in Systems Medicine aims to provide doctors and scientists with interdisciplinary theoretical and technological training in biomedical sciences to address the challenges of precision medicine. The goal is to train professionals capable of tackling highly complex technological and therapeutic strategies with multidisciplinary approaches, enabling them to: i) manage emerging areas of medicine (e.g., quantitative biology, biomarkers, personalized medicine, etc.); ii) conduct research in multidisciplinary teams focused on solving biomedical problems; and iii) analyze the economic, ethical, and/or psychosocial issues associated with research and/or disease management.
The doctoral program is organized into Research Areas proposed by the participating institutions based on their characteristics and areas of scientific excellence, such as: Cancer Biology, Computational Biology, Genomic Medicine, Immunology, Medical Humanities, Molecular and Cellular Biology, Molecular Therapy, Neurobiology, Structural Biology. These areas intersect and serve as the foundation for a broad, interdisciplinary, and multidisciplinary doctoral program that can easily incorporate other areas of expertise.
Advances in genetics and genomic sciences have triggered a revolution, transforming classical Medicine into what is now known as Precision Medicine. This new approach is based on the acquisition and integration of vast amounts of quantitative molecular data and their use for a personalized definition of disease and targeted therapy. The transition to Precision Medicine requires professionals with new skills and multidisciplinary training.
The national doctoral program in Systems Medicine aims to provide doctors and scientists with interdisciplinary theoretical and technological training in biomedical sciences to address the challenges of precision medicine. The goal is to train professionals capable of tackling highly complex technological and therapeutic strategies with multidisciplinary approaches, enabling them to: i) manage emerging areas of medicine (e.g., quantitative biology, biomarkers, personalized medicine, etc.); ii) conduct research in multidisciplinary teams focused on solving biomedical problems; and iii) analyze the economic, ethical, and/or psychosocial issues associated with research and/or disease management.
The doctoral program is organized into Research Areas proposed by the participating institutions based on their characteristics and areas of scientific excellence, such as: Cancer Biology, Computational Biology, Genomic Medicine, Immunology, Medical Humanities, Molecular and Cellular Biology, Molecular Therapy, Neurobiology, Structural Biology. These areas intersect and serve as the foundation for a broad, interdisciplinary, and multidisciplinary doctoral program that can easily incorporate other areas of expertise.
Tutte le classi di laurea magistrale - All classes master's degree
Dipartimento di Scienze della Salute - Via di Rudinì 8 - Milano (MI)
- Main offices
Dipartimento di Scienze della Salute- Via di Rudinì 8 - Milano (MI) - Degree course coordinator: Pasini Diego
Via Adamello, 16 - IFOM - Istituto FIRC di Oncologia Molecolare ed. 9
[email protected] - Degree course website
https://www.semm.it/education/phd-program-systems-medicine
| Title | Professor(s) |
|---|---|
| Unveiling the dark proteome of cancer: Defining the Existence and Therapeutic Potential of Noncanonical ORFs in Cancer |
A. Bachi (IFOM)
|
| Functional proteomics |
A. Bachi (IFOM)
|
| Modulating DNA Repair Pathways to Enhance Immune Responsiveness in Colorectal Cancer |
A. Bardelli UNITO
|
| Genomics of Cancer and Targeted Therapies |
A. Bardelli UNITO
|
| Multi-omics characterization of the cellular adaptation to suistained hypoxia |
F. Buffa (IFOM)
|
| Artificial intelligence & System Biology |
F. Buffa (IFOM)
|
| Subcellular heterogeneity of the ribosomal machinery from structure to function |
L. Calviello (HT)
|
| Deciphering the role of lncRNA in regulating genome activity |
P. Carninci (HT)
|
| Molecular mechanism of RNA modifying machines |
A. Casañal (HT)
|
| Molecular Mechanisms of RNA Editing Macromolecular Complexes |
A. Casañal (HT)
|
| When protection from autoimmunity causes aggressive B cell lymphomas: from molecular mechanisms to clinical implications |
S. Casola (IFOM)
|
| Mastering the Survival Secrets of Cancer: Unveiling and Targeting the Hidden Mechanisms Behind Cancer Therapy Resistance and Cellular Endurance | |
| Synthetic Lethality Approaches to selectively kill BRCA1 and BRCA2 Deficient Tumors by targeting DNA replication gaps | |
| The role of DNA damage-induced non coding RNA in cancer and aging |
F. d'Adda di Fagagna (IFOM)
|
| Targeting ALT-positive tumors with antisense oligonucleotides: telomere biology, mechanisms, and resistance |
F. d'Adda di Fagagna (IFOM)
|
| Telomere dynamics in aging and cancer: exploring therapeutic potential beyond cancer cells |
F. d'Adda di Fagagna (IFOM)
|
| Impact of telomere dysfunction on immune system deregulation |
F. d'Adda di Fagagna (IFOM)
|
| Investigating telomere loss during replication |
Y. Doksani (IFOM)
|
| Unraveling the Mechanisms of eccDNA Formation |
Y. Doksani (IFOM)
|
| Organization of Neuronal Nucleoli In Situ |
P. Erdmann (HT)
|
| Understanding Biomolecular Condensation in Neurodegenerative Disease Models from In Vitro to Tissue |
P. Erdmann (HT)
|
| A High-Resolution Approach to Reconstituting Excitatory Synapses |
P. Erdmann (HT)
|
| Novel senolytic targets for the treatment of age-associated diseases |
M. Kovatcheva (IFOM)
|
| Cell plasticity and aging |
M. Kovatcheva (IFOM)
|
| Investigating the developmental origins of cancer |
M. Kovatcheva (IFOM)
|
| Maladaptive cell plasticity in the progression from tissue injury to tumorigenesis |
M. Kovatcheva (IFOM)
|
| Uncovering DDR Factors that influence tumor immunogenicity |
G. Leuzzi (IFOM)
|
| Defining the impact of Single Nucleotide Variants (SNVs) on cancer immunity |
G. Leuzzi (IFOM)
|
| Molecular and functional analysis of pancreatic cancer heterogeneity |
G. Natoli (IEO)
|
| Transcriptional Control in Inflammation and Cancer |
G. Natoli (IEO)
|
| Mechanisms and functional implications of control of extragenic transcription |
G. Natoli (IEO)
|
| Molecular bases and functional implications of cellular heterogeneity in pancreatic cancer |
G. Natoli (IEO)
|
| The modulatory role of the gut microbiome on the balance between antigen-specific and bystander immune responses in solid tumors |
L. Nezi (IEO)
|
| Non-genetic mechanisms of drug-resistance in Acute Myeloid Leukemia (AML). | |
| Breast-cancer cell-phenotypes selected during metastatization and treatment. | |
| Functional and genetic characterization of Enhancer-promoter networks in breast cancer. | |
| Structural and Functional Characterization of Primary Cilia Diversity in Health and Disease |
G. Pigino (HT)
|
| Cancer Epigenetics |
P. Scaffidi (IEO)
|
| Epigenetic mechanisms in health and cancer |
P. Scaffidi (IEO)
|
| The hidden drivers of cancer |
M. Schaefer (IEO)
|
| The cancer code: unraveling selection across the cancer genome and epigenome |
M. Schaefer (IEO)
|
| Microbiome signatures of early on-set colorectal cancer risk factors |
N. Segata (UNITN)
|
| Microbiome signatures of early on-set colorectal cancer |
N. Segata (UNITN)
|
| High-resolution computational metagenomics for the study of the transmission of the human microbiome |
N. Segata (UNITN)
|
| Metagenomics, microbiome, bacterial infection |
N. Segata (UNITN)
|
| Investigating molecular and cellular determinants of B cell differentiation |
B. Soskic (HT)
|
| Dissecting gene-environment interactions in human brain development and neurodevelopmental disorders through brain organoid and single cell multi-omic modelling |
G. Testa
|
| Stem Cell and Organoid Epigenetics |
G. Testa
|
| Dissecting gene-environment interactions in human brain development through single cell resolution analysis and mathematical modelling |
G. Testa
|
| Dissecting gene-environmental interactions in human brain development through advanced organoid modelling |
G. Testa
|
| Genome editing in liver for therapy of inherited diseases |
A. Auricchio
|
| Genome editing in retina for therapy of inherited diseases |
A. Auricchio
|
| Novel AAV serotypes for efficient gene delivery in vivo |
A. Auricchio
|
| Engineering Synthetic Gene Circuits for advancing gene and cell therapy |
D. di Bernardo
|
| Investigation of intertwined relationships between healthy and mutated GLUT1 using FDA approved compounds to identify a therapeutic approach. |
P. Grumati
|
| Deciphering Variants of Unknown Significance (VUS) Through High-Throughput Functional Genomics |
D. Cacchiarelli
|
| Targeting mitochondrial turnover as a therapeutic strategy in rare and common neurodegenerative diseases. |
A. Indrieri
|
| Pharmacological activation of lysosomal hydrolases trafficking to reduce Lysosomal Storage |
D. Medina
|
| Dissecting and piloting the intracellullar tarfficking of AAVs. / |
MA. De Matteis
|
| Pharmacological approaches to correct the basic defect in cystic fibrosis. |
L.J.V. Galietta
|
| New therapies for inherited metabolic disorders\ |
N. Brunetti Pierri
|
| RNA aptamers inhibiting mutant Z α1-antitrypsin polymerization |
P. Piccolo
|
| AAV-based genome editing for liver inherited diseases with liver fibrosis |
P. Piccolo
|
| Targeting inflammation as therapeutic approach for Alpha1 Antitrypsin liver disease/ |
N. Pastore
|
| Regulation of Lysosomal Exocytosis in Health and Disease- |
C. Di Malta
|
| Lysosomal Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)- |
C. Di Malta
|
| TFEB Regulation by the Vacuolar ATPase and Its Relevance to Birt-Hogg-Dubé (BHD) Syndrome |
C. Di Malta
|
| Unraveling AAV trafficking in animal models of Inherited Retinal Disorders |
M. Cortese
|
| Lysosomal signaling in metabolic diseases |
G. Napolitano
|
| Innovative gene therapy and genome editing approaches for treatment of inherited disorders |
I. Trapani
|
| Development of AAV-based therapies for inherited kidney diseases |
L. Staiano
|
| Advancing Gene Therapy: On/Off-Target Identification Using Third-Generation Sequencing |
G. Gambardella
|
| The OFD1 puzzle: one gene several diseases |
B. Franco
|
| Study of the primary molecular events leading to cystogenesis |
B. Franco
|
| The primary cilium as a therapeutic target in bile duct cancer |
B. Franco
|
| miR-181a/b down regulation as a therapeutic approach for Leigh syndrome |
B. Franco
|
| Towards dissecting the clinical variability observed in HNF‑1β associated phenotypes |
B. Franco
|
| Biochemical and biophisical approaches to study receptor endocitosis and endosomal membrane fusion |
M.Zerial
|
| Engineered Extracellular Vesicles for personalized leukemia therapy |
M. Albanese
|
| New cancer therapeutic approaches based on engineered extracellular vesicles |
M. Albanese
|
| Unraveling oncogene-drug interactions through computational analysis of transcriptional profiles. |
B. Amati
|
| Oncogenes, Transcription and Cancer |
B. Amati
|
| Immune Engagement and Tumor Evolution in Colorectal Cancer: Biomarker Discovery through Liquid Biopsy and Multi-Omics Approaches |
A. Bardelli UNITO
|
| Genomics of Cancer and Targeted Therapies |
A. Bardelli UNITO
|
| Unravelling the design principles shaping chromosomal territories |
M. Bienko
|
| Understanding the design principles and mechanisms that shape the spatial arrangement of DNA, RNAs and proteins in the nucleus of mammalian cells |
M. Bienko
|
| Crosstalk between tumor vasculature and ovarian cancer stem cells: the new role of L1CAM |
U. Cavallaro
|
| The new role of Matrix Gla Protein in ovarian cancer stem cells and in their crosstalk with tumor microenvironment |
U. Cavallaro
|
| Ovarian cancer stem cells |
U. Cavallaro
|
| Single-cell dynamics and cancer persistence | |
| Statistical physics of cells and genomes | |
| NK cells immunotherapy in combination with NK-cell engagers for the treatment of aggressive B-cell malignancies |
E. Derenzini
|
| Cellular therapies in the field of lymphomas and acute and chronic leukemias |
E. Derenzini
|
| Dissection of regional immunity to develop novel immunotherapies against cancer |
D.Di Mitri (Humanitas)
|
| Profiling of immune system composition and immune cell dynamics in cancer patients by mean of single-cell based technologies |
D.Di Mitri (Humanitas)
|
| The molecular bases of liquid biopsy tests for precision oncology |
F. Di Nicolantonio
|
| Epigenetic biomarkers for personalized cancer detection and therapy |
F. Di Nicolantonio
|
| Genetically Encoded Shape Tags for the Localization of Ciliary Proteins |
P. Erdmann
|
| Liquid Phase Separated Compartments and the Need for Subcellular Targeting |
P. Erdmann
|
| Supporting tissues (stroma) with the study of fibroblast-matrix interaction |
N. Gauthier
|
| Understanding the roles of mechanical signals generated at the interface between membrane and cytoskeleton during tumor-associated biological events |
N. Gauthier
|
| Engineering Dual-Target CAR T-Cells for Pediatric AML |
A. Giustacchini
|
| Decoding the dependencies between Leucemic Staminal Cells and the immune microenvironment |
A. Giustacchini
|
| Investigating the role of new oncological drugs in the high-precision radiotherapy era with a focus on proton therapy (the High-Rad Project) |
B. Jereczek
|
| Radiation Oncology |
B. Jereczek
|
| Role of the morphology of neural progenitor cells during brain development |
N. Kalebic
|
| molecular and cell biological mechanisms underlying human neocortex development |
N. Kalebic
|
| Maladaptive cell plasticity in the progression from tissue injury to tumorigenesis |
M. Kovatcheva
|
| Cell plasticity and aging |
M. Kovatcheva
|
| Multimodal Characterization of Homologous Recombination Deficiency in Hormone Receptor-Positive Early Breast Cancer |
A. Marra
|
| Interception of minimal residual disease in solid malignancies |
A. Marra
|
| New Drugs and Early Drug Development for Innovative Therapies |
A. Marra
|
| Genetic determinants of microtubular damage repair and its impact on cancer treatment and neurodevelopmental disorders |
L. Mazzarella
|
| Cancer genomics and biomarker discovery |
L. Mazzarella
|
| Translational oncology |
L. Mazzarella
|
| Cancer Biology studies |
C. Missero
|
| Molecular and cellular Biology |
C. Missero
|
| Control of cellular diversity in human pancreatic cancer |
G. Natoli (IEO)
|
| Control of gene expression in inflammation |
G. Natoli (IEO)
|
| Molecular and functional analysis of pancreatic cancer heterogeneity |
G. Natoli (IEO)
|
| Transcriptional Control in Inflammation and Cancer |
G. Natoli (IEO)
|
| Mechanisms and functional implications of control of extragenic transcription |
G. Natoli (IEO)
|
| Molecular bases and functional implications of cellular heterogeneity in pancreatic cancer |
G. Natoli (IEO)
|
| Unveiling the RNA Code in Cancer: Long-Read Technologies and AI Models |
F. Nicassio
|
| Genomic approaches to the study of mechanisms in control of gene expression dynamics |
F. Nicassio
|
| Regulatory Mechanisms of Polycomb-mediated Transcriptional Repression in the Control of Cell Identity | |
| Epigenetic Mechanisms in Cancer | |
| Charting Tissue-Specific Transcriptome and Epitranscriptome in Humans Through Long-Read Sequencing Data |
G.Pesole UNIBA
|
| Development of bioinformatics methodologies and specialized databases for the analysis and functional characterization of "omics" data |
G.Pesole UNIBA
|
| Structural and Functional Characterization of Primary Cilia Diversity in Health and Disease |
G. Pigino
|
| Molecular mechanisms and principles of self-organisation in cilia and other subcellular structures that are of fundamental importance for human health and disease |
G. Pigino
|
| Investigating the supramolecular organization of HECT ubiquitin ligases |
S.Polo
|
| Molecular Machines in Signalling Pathways |
S. Polo
|
| Genomic medicine |
F. Salvatore
|
| Clinical Ethics in Oncology: Mapping Dilemmas, Conflicts, and Decision-Making Pathways |
V. Sanchini
|
| Emerging technologies and vulnerabilities in aged care |
V. Sanchini
|
| Deciphering and exploiting aneuploidy in cancer |
S. Santaguida
|
| Genome instability |
S. Santaguida
|
| Cancer Epigenetics |
P. Scaffidi (IEO)
|
| Epigenetic mechanisms in health and cancer |
P. Scaffidi (IEO)
|
| A senescence-conditional therapy to precisely resect infected cells |
E. Scarpa
|
| Chronic infections and cellular senescence |
E. Scarpa
|
| High-resolution computational metagenomics for the study of the transmission of the human microbiome |
N. Segata (UNITN)
|
| Metagenomics, microbiome, bacterial infection |
N. Segata (UNITN)
|
| Discovery and functional dissection of genetic targets of chronic human diseases through the lens of immunology |
N. Soranzo
|
| Studies how the human genome influences the risk of common diseases |
N. Soranzo
|
| Investigating molecular and cellular determinants of B cell differentiation |
B. Soskic (HT)
|
| Elucidating the genetic control of T cell – B cell interaction and antibody production |
B. Soskic (HT)
|
| Cell biology of brain development |
E. Taverna
|
| Understand how neural stem cells identity influences brain development in heath and disease |
E. Taverna
|
| Integrative structural biology of RNA Polymerase III complexes |
A. Vannini
|
| molecular mechanisms of protein complexes linked to RNApol III |
A. Vannini
|
| Epigenetic mechanisms regulating stem cell behaviour |
A. Zippo
|
| Epigenetic mechanisms in cancer dormancy |
A. Zippo
|
| Leveraging TRM cells in the tumor microenvironment for improved immunotherapy |
B. Zitti
|
| Tumor Microenvironment and Immunotherapy |
B. Zitti
|
| Exploiting synthetic-lethality toward targeted therapeutic development against MYC/BCL2-driven B-cell lymphoma.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
B. Amati (IEO Milan)
|
| Targeting Metastatic Prowess with Translational Oncology.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
A. Bardelli (UNITO)
|
| Impact of IDH Mutation on immune dynamics in gliomas.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
R. Bonecchi (Universita' Humanitas)
|
| Targeting Transcription Replication Pathways in Tumors.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
S. Campaner (UNIPD)
|
| Targeting Metabolic Reprogramming to Improve Therapeutic Outcomes in Multiple Myeloma.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
M. Cea (UNIGE)
|
| Characterization of persister cell population dynamics through high-content methods.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
M. Cosentino Lagomarsino (IFOM Milan)
|
| Replication-stress-driven placental-like programme and immune escape in aggressive human cancers.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
V. Costanzo (IFOM Milan)
|
| Overcoming poly-ADP-rybose-polymerase inhibitor resistance in ovarian carcinoma.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
G. Damia (Mario Negri)
|
| Spatial Metagenomic and Tumor Microenvironment landscape in Head and Neck Cancer for AI-Driven Immunotherapy Prediction.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
L. De Cecco (INT Milan)
|
| Dissecting the transcriptomic profile of endothelial cells (EC) in VETC+ cancers pave the way to a true personalized med.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
L. Di Tommaso (Universita' Humanitas)
|
| Analysis of DNA from cervical swabs for early detection of ovarian and p53-abnormal endometrial cancers.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
M. D'Incalci (Humanitas Mirasole spa)
|
| Genetic hallmarks of invasive and non-invasive medullary thyroid cancer.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
R. Elisei (UNIPI)
|
| Targeting PBX as a novel therapy for myeloproliferative neoplasm: effect on disease course through innovative assays.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
F. Ficara (Universita' Humanitas)
|
| Biomarkers of anti-tumor response in solid tumors treated with combination immunotherapy targeting immunosuppression.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
E. Lugli (Humanitas Mirasole spa)
|
| Decoding Natural Killer Cell Function in the Tumor Microenvironment of Women’s Cancers: from Bench to Bedside.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
E. Marcenaro (UNIGE)
|
| Targeting tumor immune-evasion mechanisms to limit the metastatic progression of human colorectal cancer to liver.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
D. Mavilio (UNIMI)
|
| Exploitation of Indocyanine green loaded engineered protein nanocages for photodynamic therapy of Breast Cancer.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
S. Mazzucchelli (UNIMI)
|
| Investigating the role of peroxisomes in modulating radiotherapy response in breast cancer.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
A. Morandi (UNIFI)
|
| Dissecting and Targeting IFI6-Driven Chemoresistance in Acute Myeloid Leukemia (AML).
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
PG. Pelicci (IEO Milan)
|
| Decoding Early Metastasis in Colorectal Cancer: The Hidden Role of Alternative Splicing.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
S. Polo (IFOM Milan)
|
| Dissecting ETP-ALL Vulnerabilities Via Single-Cell Genomics and Ex Vivo Drug Response Profiling.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
G. Roti (UNIPR)
|
| How to reduce the incidence of acute GvHD and leukemia relapse after HSCT with Treg/Tcon adoptive immunotherapy.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
L. Ruggeri (UNIPG)
|
| Molecular and clinical characterization of micronuclei in chromosomally-unstable tumors.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
S. Santaguida (IEO Milan)
|
| Novel molecular mechanisms controlling metastatic ovarian cancer cells.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
L. Tamagnone (UNICatt)
|
| Targeting pathogenesis and therapies of Thymic Epithelial Tumors at crossroad between cancer immunology and autoimmunity.
Requirements: RESERVED FOR WINNERS OF THE PUBLIC CALL FOR APPLICATIONS FOR ADMISSION TO THE DOCTORATE OF NATIONAL INTEREST IN SYSTEMS MEDICINE - PHD IN SYSTEMS MEDICINE A.Y. 2025/2026 AIMED AT GRADUATES IN MEDICINE AND SURGERY (LM-41) SPECIALISING IN THE MEDICAL FIELD WITH AN INTEREST IN ONCOLOGY RESEARCH (PHYSICIAN SCIENTIST) |
PA. Zucali (Humanitas Mirasole spa)
|
Courses list
October 2025
| Courses or activities | Professor(s) | ECTS | Total hours | Language |
|---|---|---|---|---|
| Compulsory | ||||
| Cancer biology | 2 | 10 | English | |
November 2025
| Courses or activities | Professor(s) | ECTS | Total hours | Language |
|---|---|---|---|---|
| Compulsory | ||||
| Structural Biology | 4 | 20 | English | |
Enrolment
Call for applications
Please refer to the call for admission test dates and contents, and how to register.
Application for admission: please refer to the call
Attachments and documents
Call for applications for the second session of DIN Systems Medicine
Following the programme of study
Contacts
Office and services for PhD students and companies